You are here

  • Home
  • Archive
  • Volume 71, Issue 12
  • A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies

Article metrics

Article menu

Download PDFPDF

Original article
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies

 

Online download statistics by month:

Online download statistics by month: October 2018 to March 2025

AbstractFullPdf
Oct 20181059369135
Nov 201844849072
Dec 201841742297
Jan 201925024862
Feb 201919219048
Mar 201917817439
Apr 201916816651
May 201914013939
Jun 201912212243
Jul 2019899031
Aug 201912412426
Sep 2019929023
Oct 2019858232
Nov 2019666229
Dec 2019555436
Jan 20201059938
Feb 2020797542
Mar 2020969645
Apr 2020666338
May 2020716450
Jun 2020676537
Jul 2020585724
Aug 2020636130
Sep 2020575627
Oct 2020807535
Nov 2020615539
Dec 2020595219
Jan 2021545326
Feb 2021605320
Mar 2021726945
Apr 2021998547
May 2021696722
Jun 2021686320
Jul 2021484412
Aug 2021403722
Sep 2021685821
Oct 2021493858
Nov 2021372822
Dec 2021332510
Jan 2022353127
Feb 2022342919
Mar 2022272521
Apr 2022453511
May 2022656328
Jun 2022453810
Jul 2022292710
Aug 2022454115
Sep 2022373616
Oct 202257539
Nov 2022332713
Dec 2022322614
Jan 2023221811
Feb 2023645930
Mar 2023201814
Apr 2023151312
May 2023292512
Jun 202312105
Jul 2023201414
Aug 2023292913
Sep 202314124
Oct 202329277
Nov 202338324
Dec 2023907612
Jan 202425207
Feb 202482687
Mar 202435348
Apr 202418167
May 202422207
Jun 2024252211
Jul 2024373413
Aug 202422157
Sep 2024232055
Oct 202419126
Nov 202417137
Dec 2024303011
Jan 2025584723
Feb 202537339
Mar 2025383610
Total639854442031